又一非粮企业冲刺IPO！糠醛做原料，毛利超30%

Core Viewpoint - Jiangsu Qingquan Chemical Co., Ltd. (Qingquan) plans to raise 492 million yuan through its IPO on the ChiNext board, with nearly 40% of its revenue coming from non-grain bio-based products, and a comprehensive gross profit margin of 30.22% [2][18]. Group 1: Company Overview - Qingquan is a national-level specialized and innovative "little giant" enterprise focused on the R&D, production, and sales of specialty fine chemicals and high-performance polymer materials [6]. - The company has developed a product system that includes new material monomers, green solvents, pharmaceutical and pesticide intermediates, and specialty polymer materials, widely applied in various sectors such as aerospace, wind power, automotive, electronics, medical devices, chemicals, pharmaceuticals, and pesticides [6]. Group 2: Financial Performance - From 2022 to 2024, Qingquan's revenue increased from 687 million yuan to 797 million yuan, with a compound annual growth rate of approximately 7.5% [21]. - The net profit attributable to the parent company surged from 19.96 million yuan to 91.05 million yuan, a growth of 4.6 times [21]. - The comprehensive gross profit margin improved from 23.65% in 2022 to 30.22% in 2024, indicating strong profitability driven by product structure optimization and cost control [21][22]. Group 3: Product and Market Insights - Qingquan's bio-based products include DTHFP, 2-MeTHF, and CPMK, with 2-MeTHF holding a 19% share of the global market [8][18]. - The global market for 2-MeTHF is projected to reach approximately 137 million USD in 2024, with an annual compound growth rate exceeding 20% from 2023 to 2027 [13]. - The company has established a competitive edge through its high-pressure catalytic hydrogenation technology, which enhances production efficiency and product purity [15][20]. Group 4: Investment and Future Prospects - The IPO proceeds will primarily fund the expansion of bio-based THF production capacity from 400 tons per year to 3,000 tons per year, with an investment of 130 million yuan [23]. - The bio-based materials industry is expected to accelerate from 2025 to 2030, driven by increasing policy pressures such as carbon taxes and ESG considerations [24]. - Qingquan's case illustrates that the key to the industrialization of non-grain bio-based materials lies not only in raw material supply but also in the ability to develop high-value downstream products [25].